NCT06227611

Brief Summary

The aim of the study is to evaluate the agreement between three different grids in detecting central visual field defect in early glaucoma patients with reduced ganglion cell layer thickness.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
16

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2021

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 4, 2021

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 4, 2022

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

January 18, 2024

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 29, 2024

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 4, 2025

Completed
Last Updated

February 27, 2025

Status Verified

February 1, 2025

Enrollment Period

1 year

First QC Date

January 18, 2024

Last Update Submit

February 25, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • the agreement between 10-2 HFA and 24-2c HFA in detecting central visual field defect

    central visual field is defined by the presence of a cluster of three test locations with significantly reduced sensitivity in a hemifield fo the pattern deviation plot.

    12 month

Secondary Outcomes (1)

  • the agreement between 24-2c HFA and G1 Octopus in detecting central visual field defect

    12 month

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

glaucoma patients referring to glaucoma clinic of IRCCS-Fondazione GB Bietti and University of Rome Tor Vergata.

You may qualify if:

  • glaucoma patients with glaucomatous optic nerve head defect and reduced ganglion cell layer thickness

You may not qualify if:

  • age\<18 years
  • unable to read, understand and sign the written informed consent
  • unable to perform visual field test
  • advanced glaucoma with C/D\>0.7
  • other causes of optic neuropathies
  • retinal or macular diseases
  • lens or corneal opacities
  • spherical refractive defect \>± 6D
  • cylindric refractive defect \>± 3D

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

IRCCS-Fondazione GB Bietti

Rome, Italy

RECRUITING

University of Rome Tor Vergata

Rome, Italy

RECRUITING

MeSH Terms

Conditions

Glaucoma

Condition Hierarchy (Ancestors)

Ocular HypertensionEye Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 18, 2024

First Posted

January 29, 2024

Study Start

May 4, 2021

Primary Completion

May 4, 2022

Study Completion

May 4, 2025

Last Updated

February 27, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

Locations